Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ENROLLING BY INVITATION
NCT04240821
PHASE2

Theophylline for Treatment of Pseudohypoparathyroidism

Sponsor: Ashley Shoemaker

View on ClinicalTrials.gov

Summary

Pseudohypoparathyroidism is a genetic disorder with limited treatment options, characterized by early-onset obesity, short stature, hormone resistance and cognitive impairment. This phase 2 clinical trial will test the efficacy of theophylline, a phosphodiesterase inhibitor, in pseudohypoparathyroidism. We hypothesize that theophylline will cause weight loss, improve glucose tolerance and decrease hormone resistance in children and young adults.

Official title: Open-Label Extension Study of Theophylline for Treatment of Pseudohypoparathyroidism

Key Details

Gender

All

Age Range

2 Years - 99 Years

Study Type

INTERVENTIONAL

Enrollment

34

Start Date

2020-05-22

Completion Date

2026-12-31

Last Updated

2026-02-23

Healthy Volunteers

Yes

Interventions

DRUG

Theophylline ER

Oral theophylline

Locations (1)

Vanderbilt University Medical Center

Nashville, Tennessee, United States